Paolo Tarantino: What’s distinct about Breast cancers with ERBB2? – OncoDaily
Paolo Tarantino: What’s distinct about Breast cancers with ERBB2? / Breast Cancer, cancer, ESMO Open, OncoDaily, Oncology, Paolo Tarantino
Related Articles
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer – OncoDaily
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer / Aarti R. Chawla, Abemaciclib, Bastien Nguyen, Breast Cancer, cancer, Cynthia Sandoval, Dana-Farber’s
Fact-checking Donald Trump’s claim that wind turbines kill whales – BBC News
The former president blamed wind farms for a spike in whale deaths – but his claims don’t stand up.
Artificial intelligence and mRNA vaccines are not going to cure cancer
Today I saw a video clip of Larry Ellison discussing the promise of artificial intelligence and mRNA vaccines.
New research shows the problem of health misinformation in Canada is growing
A new survey conducted by the CMA finds that health misinformation in Canada is a growing problem.
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
Background Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon…
Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment
In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous…
Renew Support for Renewable Energy
Renewable energy is crucial to the U.S. economy and the environment
Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer
Nature Immunology – To mature, dendritic cells collect and synthesize cholesterol to construct lipid nanodomains on their membranes. Obstructing this process impairs their ability to…
Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients
A Newcastle disease virus engineered to enhance anti-tumor immune responses provided a 90% rate of disease control in a clinical trial of 20 patients with…
